

FINDING ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AS POTENTIAL CNS DRUGS

A. S. Hogendorf,^{1,2} P. Brański,³ G. Burnat,³ R. Bugno,¹ A. Hogendorf,¹ B. Chruścicka,³ A. J. Bojarski.¹

- 1) Department of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343 Cracow, Poland,
- 2) Department of Organic Chemistry, Jagiellonian University, 3 Ingardena Street, Cracow, Poland,
- 3) Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343 Cracow, Poland.



Motivation

Glutamate is the main excitatory neurotransmitter in the central nervous system (CNS). It is an essential molecule, e.g. for cognitive functions such as memory formation and learning.¹


Group III metabotropic glutamate receptors (mGluR₄, mGluR₆, mGluR₇ and mGluR₈) are considered promising drug targets for treatment of neurological disorders e.g. Parkinson's disease, schizophrenia, major depressive disorder and pain.² Apart from the traditional concept of finding orthosteric ligands, mGluR allosteric modulation is considered a very promising approach.³ Due to little differences in the aminoacid sequences of orthosteric binding sites of mGluR₄, mGluR₇ and mGluR₈, finding selective ligands is notoriously difficult.

mGluR₈ receptor, which is positively coupled to G_{α(i/o)}, functions as a presynaptic autoreceptor. GRM8 polymorphism may be involved in pathogenesis of schizophrenia.⁴ Activation of mGluR₈ can elicit both hyperalgesic and analgesic effects. Behavioural experiments suggest that mGluR8 plays role in regulation of anxiety. mGluR₈ knockout (KO) mice exhibit an anxiety phenotype further implying involvement of this receptor in mood regulation.⁵

Background and methodology

Chemistry:

Compounds **AH-48**, **MAH-14** and **MAH-15** were synthesized, purity examined by LC-MS, structure confirmed by ¹H NMR and ¹³C NMR. Elemental analysis is consistent with calculated values.



AZ 12216052

mGluR8 PAM


Biological assays:

Cell line: Host: T-RexTM-293 cell line

Final cell lines: HEK293_T-REX-293_hmGluR8

Direct quantitative determination level of cAMP by Homogenous Time-Resolved Fluorescence

AZ 12216052 - mGluR₈ Positive Allosteric Modulator has been used in the experiments as a reference.




(S)-3,4-DPCG


mGluR8 agonist

Outcome


mGluR8, DR: L-Glu, DR: L-Glu + 1 uM MAH14, DR: L-Glu + 1 uM AZ12216052




Response to the agonist L-Glu in presence of AH-48




Response to the agonist (S)-3,4-DPCG in presence of AH-48




mGluR8, DR: L-Glu, DR: L-Glu + 1 uM AH48, DR: L-Glu + 1 uM AZ12216052




Activity of AH-48 in operational model




Activity of AH-48 in operational model




mGluR8, DR: L-Glu, DR: L-Glu + 1 uM MAH15, DR: L-Glu + 1 uM AZ12216052



Response to the agonist L-Glu in the presence of AZ12216052



Activity of AZ12216052 in operational model



Summary and outlook

We have synthesized and evaluated chemical scaffold exhibiting potential mGluR₈ Positive Allosteric Modulator activity along with a strong agonistic component.

AH-48 has the following characteristics:

- activates mGluR₈ as an agonist (EC₅₀ = 2.6 uM),
- acts as a Positive Allosteric Modulator (EC₅₀ = 4.3 uM in the presence of 1 uM L-Glu),
- Activity of **AH-48** with or without presence of L-Glu is completely abolished by 10uM of LY341495
- **AH-48** activates mGluR₄ and mGluR₇,

MAH-14 acts as a mGluR₈ PAM (EC₅₀ = 4.4uM)

MAH-15 acts as a mGluR₈ PAM (EC₅₀ = 5.7uM)

We plan further tests (metabolic stability, genotoxicity, anti-target assays) which will help us establish lead structure in the study.

References

1. McEntee W. J., Crook T. H., *Psychopharmacology*, 111 (1993) 391-401,
2. Hovelsø N., Sotty F., Montezinho L. P., Pinheiro P. S., Herrik K. F., Mørk A., *Curr Neuropharmacol.*, 10 (2012) 12-48,
3. Flor P. J., Acher F. C., *Biochem. Pharmacol.*, 84 (2012) 414-424,
4. Robbins M. J., Starr K. R., Honey A., Soffin E. M., Rourke C., Jones G. A., Kelly F. M., Strum J., Melarange R. A., Harris A. J., Rocheville M., Rupniak T., Murdock P. R., Jones D. N., Kew J. N., Maycox P.R., *Brain Res.*, 1152 (2007) 215-227,
5. Duvoisin R. M., Villasana L., Davis M. J., Winder D. G., Raber J., *Behav. Brain Res.*, 221 (2011) 50-54.

Acknowledgements

The study was partially supported by the Polish-Norwegian Research Programme operated by the National Centre for Research and Development under the Norwegian Financial Mechanism 2009-2014 in the frame of Project PLATFORMex (Pol-Nor/198887/73/2013). Databases in this study were created using ChemAxon JChem software